Intellectual property (IP) plays a key role in South Korean drug registration by providing patent protection for new pharmaceutical products. Companies must disclose IP rights during the application process, and regulatory data protection ensures exclusivity for a set period, preventing generic competitors... Read More
Drug recalls in South Korea are managed by the Ministry of Food and Drug Safety (MFDS). The MFDS coordinates recalls based on product safety issues, issuing recall orders for voluntary or mandatory action. Manufacturers must notify stakeholders, remove affected products, and report... Read More
South Korea monitors drug side effects after approval through its pharmacovigilance system, managed by the Korea Institute of Drug Safety and Risk Management (KIDS). Healthcare professionals and patients report adverse drug reactions, which are analyzed for safety signals. The Ministry of Food... Read More
In South Korea, drug labeling requirements are regulated by the Ministry of Food and Drug Safety (MFDS). Labels must include the drug’s name, active ingredients, dosage, usage instructions, expiration date, storage conditions, side effects, and manufacturer information. The labeling must be in... Read More
Drug patents in South Korea are handled by the Korean Intellectual Property Office (KIPO). Patents provide exclusive rights for up to 20 years from the filing date. Patent linkage ensures that generic drugs cannot be approved until the original drug’s patent expires,... Read More
Post-marketing surveillance in South Korea is required to monitor drug safety and efficacy after approval. Manufacturers must conduct periodic safety updates, report adverse drug reactions, and submit safety data to the Ministry of Food and Drug Safety (MFDS). This process ensures ongoing... Read More
South Korea facilitates the registration of rare disease drugs through an expedited approval process managed by the Ministry of Food and Drug Safety (MFDS). These drugs, often classified as orphan drugs, may receive regulatory support, fee reductions, and extended market exclusivity to... Read More
South Korea’s fast-track drug approval process, managed by the Ministry of Food and Drug Safety (MFDS), accelerates the review of drugs addressing serious, life-threatening, or unmet medical needs. Eligible drugs receive priority evaluation, reducing approval timelines while maintaining safety and efficacy standards,... Read More
In South Korea, new combination drugs are registered through the Ministry of Food and Drug Safety (MFDS). Applicants must provide data demonstrating the safety, efficacy, and rationale for combining the ingredients. Clinical trials or literature reviews are required to prove that the... Read More
The sponsor plays a key role in drug registration by submitting the necessary documentation, conducting clinical trials, and ensuring compliance with regulatory requirements in South Korea. The sponsor liaises with the Ministry of Food and Drug Safety (MFDS), providing safety, efficacy, and... Read More